Teva Pharmaceuticals USA, Inc recalls Amoxicillin and Clavulanate Potassium for Oral Suspension USP
- Recalling company
- Teva Pharmaceuticals USA, Inc
- Product
- Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 200 mg/28.5 mg per 5mL, 100 mL (when reconstituted), Rx only, manufactured in Canada by: Teva Canada Limited, Toronto, Canada M1B 2K9; Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054 NDC 0093-2277-7.
- Reason
- Subpotent drug; Clavulanate Potassium component
- Classification
- Class II – may cause temporary or medically reversible health consequences
- Recall date
- Oct 13, 2025
- Reported
- Nov 12, 2025
- Distribution
- Distributed in three (3) States: MS, OH, CA.
- Status
- Ongoing
- Quantity
- 4680 cartons
- Lot / codes
- Lot # 100062316, Exp Date: 01/2026
- Company location
- Parsippany, NJ
- Recall type
- Voluntary: Firm initiated
- Recall number
- D-0151-2026
- Agency
- U.S. Food and Drug Administration (FDA)
View official FDA notice ↗ Search recall number D-0151-2026 in the FDA Enforcement Report. Also see FDA recall press releases.
If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.